Compare Incyte Corporation (INCY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vistra Corp — how do they compare? Incyte Corporation trades at $117.91 (market cap $23.11B), while Vistra Corp trades at $163.85 (market cap $53.27B). The key difference: Vistra Corp is far larger — about 2.3× Incyte Corporation's market cap, and Vistra Corp pays a 0.58% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VST | |
|---|---|---|
Market Cap | $23.11B | $53.27B |
Sector | Health | Technology |
52-Week High | $118.52 | $217.92 |
52-Week Low | $67.38 | $134.71 |
Enterprise Value | $19.13B | $75.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Vistra Corp (VST) trades at $157.99, up 1.64% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings beat ($2.87 vs $1.32 expected) after previous misses, with 2026 revenue projected at $19.4B and net profit margin improving to 11.52%. Recent news highlights Vistra's positioning as a potential beneficiary of AI-driven power demand growth.
Wall Street maintains strong bullish sentiment with 91% buy ratings and a $253 consensus price target representing 60% upside potential. Key risks include power price volatility, high debt levels, and project execution challenges. The company's long-term power purchase agreements with major tech firms provide revenue visibility, but investors should monitor Q2 2026 earnings due August 7th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
